Gyroscope Therapeutics Limited
Clinical trials sponsored by Gyroscope Therapeutics Limited, explained in plain language.
-
Gene therapy trial for dry AMD halted early
Disease control TerminatedThis study tested a single injection of GT005 gene therapy in 56 people with dry age-related macular degeneration (AMD), a leading cause of vision loss. The goal was to check safety and whether it could slow disease progression. The trial was terminated early, so results are limi…
Phase: PHASE1, PHASE2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 22, 2026 12:05 UTC
-
Gene therapy injection for dry AMD shows promise in early trial
Disease control TerminatedThis study tested a single injection of a gene therapy called GT005 into the eye for people with geographic atrophy, a severe form of dry age-related macular degeneration that causes vision loss. The trial included 255 adults aged 55 and older. The goal was to see if the treatmen…
Phase: PHASE2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 17, 2026 12:03 UTC
-
Gene therapy shot for dry AMD shows promise in early trial
Disease control TerminatedThis study tested a single injection of a gene therapy called GT005 in 98 people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes vision loss. The goal was to see if the treatment could slow the growth of damaged areas in the eye and c…
Phase: PHASE2 • Sponsor: Gyroscope Therapeutics Limited • Aim: Disease control
Last updated Jun 10, 2026 13:24 UTC